

Host-Pathogen Interactions in *Campylobacter* Infections: the Host Perspective

Riny Janssen,¹ Karen A. Krogfelt,² Shaun A. Cawthraw,³ Wilfrid van Pelt,⁴
Jaap A. Wagenaar,^{5,6,7,8} and Robert J. Owen^{9*}

Laboratory for Health Protection Research, National Institute for Public Health and the Environment, Bilthoven, The Netherlands¹; Unit of Gastrointestinal Infections, Statens Serum Institut, Copenhagen, Denmark²; Department of Food and Environmental Safety, Veterinary Laboratories Agency, Addlestone, Surrey, United Kingdom³; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands⁴; Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands⁵; Animal Sciences Group,⁶ WHO Collaborating Centre for *Campylobacter*,⁷ and World Organization for Animal Health (OIE) Reference Laboratory for *Campylobacteriosis*,⁸ Lelystad, The Netherlands; and Gastrointestinal, Emerging, and Zoonotic Infections Department, Health Protection Agency Centre for Infections, London, United Kingdom⁹

INTRODUCTION	505
PATHOLOGY AND PATHOPHYSIOLOGY OF <i>CAMPYLOBACTER</i> INFECTION	507
SEQUELAE OF <i>CAMPYLOBACTER</i> INFECTION	507
ROLE OF HUMAN IMMUNITY IN <i>CAMPYLOBACTER</i> DISEASE	509
Epidemiological Observations.....	509
Observations of Patients.....	509
Innate Immunity to <i>Campylobacter</i>	510
Humoral Immunity to <i>Campylobacter</i>	510
Role of Humoral Immunity in Protection	511
Cellular Immunity	511
LESSONS LEARNED FROM EXPERIMENTAL INFECTION	511
In Vitro Models of Infection.....	511
Animal Models of Infection.....	512
Human Volunteer Studies.....	513
VACCINE-INDUCED PROTECTION	513
FUTURE DIRECTIONS	513
ACKNOWLEDGMENTS	514
REFERENCES	514

INTRODUCTION

Campylobacter is a major cause of acute bacterial diarrhea in humans worldwide (3). The incidence of human campylobacteriosis increased exponentially during the last decade of the 20th century (183), although part of this increase can be attributed to better detection of *Campylobacter* and better diagnosis. At the start of the 21st century, this increase has stopped, as shown by data for the total number of *Campylobacter* cases in the European Union until 2003 (Fig. 1). In humans, the clinical symptoms of campylobacteriosis are watery or bloody diarrhea, abdominal cramps, and nausea (151). In a small subgroup of patients, the acute phase is followed by serious sequelae: Guillain-Barré syndrome (GBS) and reactive arthritis (78, 86). Acute diarrhea, *Campylobacter*-related mortality, and residual effects of GBS are the main determinants contributing to this disease burden (79). Campylobacteriosis in humans is induced mainly by *Campylobacter jejuni* (about 90% of cases), and the remaining fraction is induced predominantly

by *Campylobacter coli*. *Campylobacter* is part of the normal intestinal flora of birds, and humans are not the reservoir for infection. As a result, poultry is a major source of infection. The estimation of incidence of *Campylobacter* enteritis in the population is usually based on confirmed cases corrected for several factors like the proportion of patients consulting a physician and the number of this group submitting a stool sample for *Campylobacter* isolation. Because the infection is usually self-limiting, the true population incidence is estimated to be 8 to 30 times higher than confirmed cases, depending on the country (148, 166, 179).

The estimated rate of campylobacteriosis (number of cases/100,000 individuals) differs strongly around the world, with New Zealand as the country with the highest rate (396/100,000 persons), compared to, e.g., the United States (reported as being 12.7/100,000 persons by FoodNet in 2005) (13, 44). The excessive rate in New Zealand seems to be real, but it remains unexplained. New Zealand's campylobacteriosis epidemic reached a new peak in May 2006, with the annualized national notification rate exceeding 400 per 100,000 individuals for the first time, the highest national rate reported in the literature (12). Differences among countries should be considered with care, as surveillance and reporting systems may differ markedly from country to country. For example, differences among countries within the European Union have been reported: the

* Corresponding author. Mailing address: Gastrointestinal, Emerging, and Zoonotic Infections Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5HT, United Kingdom. Phone: 44 20 8327 6740. Fax: 44 20 8905 9929. E-mail: robert.owen@hpa.org.uk.




FIG. 1. Total number of confirmed *Campylobacter* cases in the European Union until 2003. Data after 2003 are not shown because several new European Union (EU) member states with a high reported incidence of campylobacteriosis joined the European Union (Table 1).

Czech Republic reported an incidence of 303/100,000 individuals, whereas other countries did not report a single case (Table 1). It is highly unlikely that these differences are real. There is little information about mortality due to campylobacteriosis. It is estimated that in The Netherlands (population of about 16,000,000 individuals), with an estimated incidence of campylobacteriosis of about 59,000 cases, around 25 people die of *Campylobacter* infection every year (92). Most *Campylobacter* infections occur as sporadic cases, and outbreaks are rare or are not recognized. The few reported outbreaks are most commonly associated with raw milk or water (57, 98, 139, 153, 159). This is surprising for a food-borne pathogen, although it is known that the dose of *Campylobacter* present in food is highly variable. Better monitoring of possible outbreaks is essential to increase our understanding of the epidemiology of campylobacteriosis in humans. Such outbreaks also provide a unique opportunity to study host responses to *Campylobacter*, for instance, by measuring immune parameters in cases and exposed controls. Although poultry is a major source of infection, it is estimated that in The Netherlands, only 20% to 40% of all laboratory-confirmed cases are attributable to the consumption of undercooked chicken (80). This percentage is in agreement with estimates from Belgium (40%), where the withdrawal of poultry meat from the market following dioxin contamination of chicken feed resulted in a clear decline in human campylobacteriosis incidences (171). Other risk factors include drinking raw milk or contaminated water, traveling abroad, and contact with pets. However, a large proportion of all infections (i.e., approximately 50%) cannot be attributed to any of the known risk factors, indicating that other sources exist. Although humans are also most probably exposed to *Campylobacter* from currently unknown sources, the exposure of humans to poultry meat is the best-understood source, and consequently, most effort is put into *Campylobacter* control strategies along the poultry meat production chain. However, extensive control strategies with the overall aim to reduce *Campylobacter* contamination on poultry meat have been only partly successful. We conclude that humans will be continuously exposed to *Campylobacter* from poultry meat, from sources where interventions cannot be implemented (contact

with pets), and from unknown sources. As exposure will not be equally distributed in the population (pet owners and professionally exposed humans) and the population will not be equally susceptible (children and the elderly), we urgently need more understanding of the pathogen-host interaction. Only with this knowledge can science-based risk assessments be performed and science-based intervention strategies be developed. Since the exposure of the population to *Campylobacter* cannot be prevented, it is crucial to understand the risks involved with exposure and to identify groups in the population that are more at risk. Currently available risk assessment models do not explicitly take into account that individuals display differential susceptibility to infection. A better understanding of the pathogenic mechanisms of *Campylobacter* and, importantly, of the host factors involved in the defense against *Campylobacter* infection may lead to the identification of risk factors in the population. It is conceivable that the efficacy of some of these host factors in the defense against *Campylobacter* is genetically determined. Studying these host factors could contribute both to novel intervention strategies and to the development of more realistic risk assessment models that incorporate such host susceptibility factors and/or more targeted intervention strategies.

TABLE 1. Reported campylobacteriosis cases in humans and incidence of cases in Europe in 2005^a

Country	No. of confirmed cases	No. of confirmed cases/100,000 individuals
Austria	5,065	61.7
Belgium	6,879	65.8
Cyprus	0	0
Czech Republic	30,268	302.7
Denmark	3,677	68
Estonia	124	9.2
Finland	4,002	76.4
France	2,049	3.3
Germany	62,114	75.3
Greece	— ^b	—
Hungary	8,288	82.1
Ireland	1,794	43.7
Italy	—	—
Latvia	0	0
Lithuania	694	20.3
Luxembourg	194	42.6
Malta	91	22.6
The Netherlands	3,761	46.2
Poland	47	0.1
Portugal	—	—
Slovakia	2,204	40.9
Slovenia	0	0
Spain	5,513	12.8
Sweden	5,969	66.2
United Kingdom	52,686	88.5
European Union total	195,419	51.6
Iceland	128	43.6
Norway	2,631	57.1
Total	198,178	51.7

^a Adapted from reference 54.

^b —, no cases reported.

The scope of this review is to summarize available data on host factors involved in the response to *Campylobacter jejuni* and how these factors can increase our understanding of host-pathogen interactions. In other diseases, the majority of such factors are elucidated by studying infection in murine models with well-defined genetic mutations in host defense mechanisms. However, *Campylobacter* does not induce disease in wild-type mice, and rodent models that mimic human disease have been lacking. Recent progress in the generation of gene-deleted mice has now resulted in the development of murine models, which have contributed to our understanding of the defense against *Campylobacter* and will be valuable for further studying host responses to *Campylobacter* infection (discussed below) (63, 106, 177).

This study was aimed at summarizing the current understanding of host mechanisms involved in the defense against *Campylobacter* by evaluating data available from three sources: (i) epidemiological observations, (ii) observations of patients, and (iii) experimental observation including observations of animal models and human volunteer studies.

PATHOLOGY AND PATHOPHYSIOLOGY OF *CAMPYLOBACTER* INFECTION

Humans are orally exposed to *Campylobacter*. During passage through the acidic environment of the stomach, a large proportion of the ingested dose may be killed, depending on the buffering capacity of the food. The remaining bacteria can survive and are able to adhere to intestinal epithelial cells or to the mucus overlying these cells and replicate in the intestine. In infected individuals, this can result either in asymptomatic colonization status, i.e., bacteria are present in the intestine but do not induce disease (41, 45), or in diarrheal illness. *Campylobacter* is highly infectious, and infective doses as low as 500 to 800 CFU have been reported (23, 140). A probability of 2% for any CFU to establish infection was calculated in a volunteer experiment (23, 160).

The colonization status in humans is reminiscent of that found in various rodents, mammals, and birds. Chickens can be colonized with as many as 10^9 CFU *C. jejuni* per gram cecal contents (43), and colonized mice can shed up to 10^6 CFU per mg feces (18). Studies of children in developing countries have shown that rates of asymptomatic carriage of *Campylobacter* in children are around 15% (108, 131), suggesting that some acquired immunity is induced from multiple exposures during early childhood. Wheeler et al. reported a rate of asymptomatic carriage of 0.7% in a population study involving adults in the United Kingdom (179). This indicates that bacterial clearance is inefficient and raises questions about how effective the immune response is in clearing all bacteria. The difference between humans and rodents is that in the latter, *Campylobacter* fails to cause diarrheal illness, indicating that animals lack specific factors, e.g., receptors, necessary for *Campylobacter* to cause disease, that effective immune mechanisms are present in animals that prevent the development of clinical disease, or that disease-causing host responses are absent.

After colonization of the intestine, clinical disease may occur. Based on clinical syndromes found in patients, two mechanisms by which *Campylobacter* can induce disease were postulated (85): (i) adherence of *Campylobacter* to the intestine

and the production of toxins (173), which alter the fluid reabsorption capacity of the intestine, resulting in secretory diarrhea, and (ii) bacterial invasion and replication within the intestinal mucosa accompanied by an inflammatory response resulting in blood-containing, inflammatory diarrhea.

In immunocompetent individuals, disease is restricted to the intestine, although bacteremia has been observed. The reported incidence for bacteremia ranges from 1.5 to 8 in 1,000 individuals (89, 152). Occasionally, passage through the intestinal mucosa and migration to extraintestinal sites via the lymphatic system result in systemic disease. However, it is important to note that systemic disease is very rare in immunocompetent individuals.

Clinical disease is characterized by acute diarrhea accompanied by intense abdominal pain. Campylobacteriosis is an inflammatory enteritis that is initially found in the small bowel and later affects the colon and the rectum (23). The incubation time is 1 to 7 days (mean, 3 days), which is longer than the incubation times of most other intestinal pathogens. The diarrhea can be either watery or, in almost one-third of the cases, bloody (79, 151, 174), indicating that the extents of intestinal inflammation vary among individuals. Inflammatory diarrhea points to a role for polymorphonuclear leukocytes (PMN) in pathology and suggests that infection can lead to extensive intestinal damage either as a direct result of bacterial toxins or as a result of the inflammatory infiltrate. It has been shown that this is in part related to differences in properties of the infecting strain (23, 60). Usually, diarrhea begins to ease after 3 to 4 days, but *Campylobacter* can be found in the feces for several weeks (89). Using a highly sensitive culture-based detection assay, Kapperud et al. observed carriage in 16% of individuals during convalescence, with a median carriage time of 31 days (89). Although a large proportion of the patients feel nauseous, only about 15% of patients vomit (151, 174). In 30% of patients, the disease does not start with diarrhea but with a prodrome of influenza virus-like symptoms such as fever, headache, dizziness, and myalgia (reviewed in reference 151), indicating that there is some systemic, probably immune-mediated, effect of local infection. Patients that suffer from such a prodrome tend to have more serious disease than patients without the prodrome, but the reasons for this are currently unknown (reviewed in reference 151).

In most immunocompetent individuals, campylobacteriosis is a self-limiting disease, and treatment with antimicrobials reduces the period of fecal shedding but does not have a large impact on the duration of disease symptoms (4, 105, 180). However, when given early, some clinical benefit has been observed (126, 147). When patients suffer from recurrent or systemic *Campylobacter* infection, antimicrobial treatment is indicated. However, an increase in antimicrobial resistance, especially fluoroquinolone resistance, in both human and animal isolates has been observed over the last decade (93, 167).

SEQUELAE OF *CAMPYLOBACTER* INFECTION

While *Campylobacter* enteritis is usually self-limiting and the disease is resolved within 1 week in the majority of cases, some individuals develop sequelae after the acute phase. Approximately 1 in 1,000 infected individuals develops GBS, a serious autoimmune-mediated neurological disorder that

can cause symptoms ranging from weakness of extremities to complete paralysis and respiratory insufficiency (reviewed in reference 116). Mortality rates due to GBS in the industrialized world are 2% to 3%, although the majority of patients recover completely within 6 to 12 months (182). In The Netherlands, the health burden for *Campylobacter*-associated GBS was estimated at 164 disability-adjusted life years in 2004 (92). Miller-Fisher syndrome, a subvariant of GBS that affects predominantly the nerves that govern eye movement, has also been associated with *Campylobacter* infection (138, 187).

GBS is thought to occur because of molecular mimicry between lipooligosaccharide, a component of the cell envelope of *Campylobacter*, and sugar moieties on nerve gangliosides (6, 9, 117, 189). Antibodies that are raised during infection with *Campylobacter* serotypes containing such ganglioside mimics can cross-react with gangliosides in some individuals, leading to the demyelination of nerves and the degeneration of axons (for a review, see reference 181). Evidence suggests that both strain properties and host properties play a role in determining the development of GBS. For instance, serotype HS:19 was overrepresented in Japanese GBS patients (97, 188) but not in United Kingdom patients (138), indicating a role for host factors. In addition, although ganglioside-mimicking structures were found more frequently in neuropathy-associated *Campylobacter* strains than in strains isolated from patients with diarrhea (7), strains that contain these ganglioside mimics are also often found in patients with uncomplicated enteritis (117). Recently, it was shown that specific types of the lipooligosaccharide biosynthesis gene locus are important for the expression of ganglioside mimics and the induction of antiganglioside antibodies (73). Taken together, these data suggest that although the presence of ganglioside mimics is important, it is not the only factor that determines the development of GBS. Currently, the role of host genetic factors in determining if GBS evolves upon infection with *Campylobacter* strains with ganglioside mimics is studied extensively. A complete review of all factors associated with the development of GBS is beyond the scope of this review (for reviews on this issue, see references 86 and 116), but some of the genetic factors that have recently been associated with the development or severity of GBS are listed in Table 2. Not only *Campylobacter* but also other pathogens have been associated with the development of GBS. However, most of the genetic studies on susceptibility to GBS are performed with GBS patients, irrespective of the causative pathogen. Therefore, host factors that determine susceptibility to GBS may shed more light on processes involved in breaking tolerance to self-antigens than on susceptibility to diarrheal illness. Further studies are needed to investigate if similar mechanisms are also involved in determining susceptibility to *Campylobacter*-induced diarrhea.

Other immune-mediated sequelae of *Campylobacter* infection include reactive arthritis (22, 101, 164) and Reiter syndrome, an inflammatory disease with either conjunctival or urethral inflammation (91). Symptoms of reactive arthritis usually occur around 14 days after infection (range, 3 days to 6 weeks), and the estimated incidence of reactive arthritis in community outbreaks ranges from 0 to 7% (53, 92, 109, 111).

TABLE 2. Genetic factors studied in association with the development of GBS or *Campylobacter*-associated GBS

Gene studied	Association with GBS	Association with <i>Campylobacter</i> -induced GBS ^a	Reference
MMP9	Yes, severity	NS	68
TNFA	Yes, severity	NS	68
IL-10	No	NS	68
IL-10	No	NS	68
CD1	Yes, incidence	NS	37
MBL2	Yes, severity	NS	70
HLA class II	Yes, severity	NS	71
HLA-DRB1	No	Nonsignificant association (trend)	103
HLA B54	Yes, incidence	Yes, incidence	95
HLA-Cw1	No	Yes, incidence	95
FCGR2A	Yes, incidence/severity	NS	165
FCGR3A	No	NS	165
FCGR3B	No	NS	165
FCGR3B	Yes, severity	NS	170
FCGR3B	Yes, severity	NS	169
IL-10	Yes, incidence	NS	115
FAS/CD95	Yes, GM1 antibodies	NS	69
CD14	No	No	56
TLR4	No	No	56
APOE	No	NS	136
TNFA	NS	Yes, incidence	102

^a NS, not studied.

Reactive arthritis is associated with HLA-B27, and various gastrointestinal pathogens can lead to its development (149). The symptoms appear to be similar regardless of the associated bacterial infection, indicating a role for factors common to a range of pathogens (149). Usually, these joint symptoms resolve completely. There are also a few case reports of *Campylobacter*-associated hemolytic-uremic syndrome, which is a well-known sequela of infection with verocytotoxin (Shiga toxin)-producing *Escherichia coli* strains (151). *Campylobacter* strains have also been isolated from patients with inflammatory bowel disease (IBD) such as Crohn's disease and have been associated with flare-ups of IBD, although a causal link between the two is still under debate (21, 67, 178). A recent registry-based study in Denmark revealed very strong associations between *Campylobacter* infection and the development of IBD, but this association still needs to be confirmed (81). A link between infection by enteric pathogens, including *Campylobacter*, and irritable bowel syndrome was also observed (52, 81, 156, 162). These enteric infections result in damage to the mucosa and disruption of the native gut flora, which could lead to prolonged bowel dysfunction (156). In a small-scale patient study, a correlation between persistently changed bowel habits following *Campylobacter* infection and the in vitro toxicity of the infecting strain was observed (162). There is laboratory evidence for a number of *Campylobacter* toxins (reviewed in reference 173), although, to date, the only toxin cloned, sequenced, and identified from genome sequences is cytolethal distending toxin (CDT), and no direct role for this toxin in the etiology of irritable bowel syndrome has so far been demonstrated.




FIG. 2. Schematic representation of host-pathogen interactions in campylobacteriosis. Pathogen-host encounters in a certain environment can either lead to infection or not. Infected individuals can then remain asymptomatic or go on to develop disease. To what extent this leads to the induction of protective immunity is currently unknown.

ROLE OF HUMAN IMMUNITY IN *CAMPYLOBACTER* DISEASE

Epidemiological Observations

Many *Campylobacter* types are encountered by the human host, but these types will probably lead to disease in only a minority of cases. Apparently, not every encounter results in the development of disease. Both bacterial virulence factors and host susceptibility factors are thought to be involved in determining if disease develops. In addition, environmental factors such as the matrix in which *Campylobacter* is consumed and the acidity of the stomach are involved (Fig. 2). Exposure is obviously a critical factor in the development of disease, and although hypothetical, a higher incidence in rural areas than in urban areas is often explained as a result of higher exposure in rural areas (58, 74, 161). In accordance with this hypothesis, it was found that in rural areas, like in developing countries, the age distribution was shifted to younger ages than in urban areas (58, 74). However, it is believed that frequent exposure can also result in the development of a certain level of basal immunity to *Campylobacter* (see also the section on developing countries below). Such responses probably do not lead to protection against a broad range of serotypes. Epidemiological support for this assumption came from data reported recently by Miller et al., which showed that infections with common and rare types of *Campylobacter* occur in different age groups, where the rare types are overrepresented in the older age groups (110). This indicates that basal immunity to commonly encountered serotypes occurs but that a broad level of protection against all serotypes does not develop. However, since even rare serotypes will have structures in common with common serotypes, this observation warrants further investigation.

The fact that not every individual displays the same susceptibility to *Campylobacter* infection can also be concluded from a range of other epidemiological observations. When outbreak data are analyzed, it is clear that not every person exposed to a certain dose of *Campylobacter* either will be colonized or will develop disease. These differences can be associated with non-specific factors such as stomach content and, related to this, the acidity of the stomach. Indeed, the use of proton pump inhibitors in the month prior to *Campylobacter* infection was shown

to increase the risk of clinical disease by as much as 10-fold (121). However, innate and specific immune factors may also play a role in determining the susceptibility of an individual to *Campylobacter* infection.

In developing countries, the incidence of *Campylobacter* enteritis peaks in children and declines clearly after childhood. In industrialized countries, *Campylobacter* disease peaks in children as well, but the steep decline does not occur but peaks again at a young adult age and declines gradually afterwards (66). The course of disease is generally more severe; i.e., infection is more often accompanied by bloody diarrhea (64, 127). In addition, it is thought that after the peak in childhood, in the developing world, asymptomatic infections are more common than in the industrialized world. In the developing world, children are frequently exposed to *Campylobacter* infection early in life due to contaminated drinking water and close contact with animals and therefore have elevated *Campylobacter*-specific antibody levels compared to those of children in the United States (25, 30, 107). In Thailand, bloody diarrhea was most often associated with disease in the first year of life, suggesting an association with primary infection (158). However, the occurrence of asymptomatic carriage in developing (and industrialized) countries (127) suggests that any immunity acquired following exposure protects against disease rather than colonization.

Observations of abattoir workers in Sweden (41, 45) support the idea that frequent exposure to *Campylobacter* induces protection against disease. Recently employed and presumably immunologically naïve workers suffered many more episodes of *Campylobacter* diarrhea than workers who were employed for many years. Consistent with the observation in the developing world, the latter group of workers regularly succumbed to asymptomatic infection with *Campylobacter* (41, 45). These data indicate that humans can develop immunity to *Campylobacter* disease, but probably not to colonization, although this immunity seems to be short-lived, and data suggest that frequent exposure to multiple serotypes/immunotypes may be necessary to boost this immunity.

In conclusion, these epidemiological observations indicate that differences in immune responses are observed in various individuals and due to differences in exposure, but to what extent they are determined by host factors, or if they are related to frequency of exposure, remains to be established. It is also clear that the acidity of the stomach is a crucial early defense mechanism against *Campylobacter*, although this is not specific for *Campylobacter* and has also been observed for other pathogens such as *Salmonella* (50, 51).

Observations of Patients

Certain groups of patients are more susceptible to *Campylobacter* disease than the general population. Two groups of patients that are particularly susceptible are those with hypogammaglobulinemia, who suffer from defects in humoral immunity, and those with AIDS, who suffer from a defect in cell-mediated immunity (134, 151). Such patients often experience more severe clinical disease that is more frequently accompanied by bacteremia. The incidence of *Campylobacter* disease in AIDS patients was shown to be 40-fold higher than that in the general population (155). Chronic carriage and

recurrent infection are also more frequently found in these highly susceptible patients, and repeated courses of antimicrobial treatment are often indicated. Severe *Campylobacter* infection is found in AIDS patients both in the industrialized world and in developing countries (47).

The genetic causes of the above-mentioned immunoglobulin deficiencies can be a result of a whole range of primary or acquired immune deficiencies (reviewed in reference 61). These patients are susceptible not only to *Campylobacter* but also to a whole range of other pathogens. The most frequent cause of hypogammaglobulinemia is common variable immunodeficiency, a heterogeneous disease that occurs in approximately 1:50,000 to 1:100,000 Caucasians. Mutations in the gene encoding ICOS, an inducible T-cell costimulatory molecule essential for proper B-cell activation, is one genetic cause of common variable immunodeficiency (75). Agammaglobulinemia is a very rare but serious recessive X-linked disease that is usually caused by a mutation in Bruton tyrosine kinase, an enzyme essential for B-cell maturation (163, 172).

From those observations, it can be concluded that various (genetically determined) immune-related host factors are involved in susceptibility to *Campylobacter* infection, although it has to be taken into account that all the above-mentioned diseases lead to severe immune defects resulting in susceptibility to a whole range of pathogens. Since hypogammaglobulinemic/agammaglobulinemic patients and AIDS patients are subject to prolonged symptoms and repeated infection, these data do suggest a role for humoral and T-cell immunity in limiting the infection (8, 134). However, they do not explain the susceptibility specifically to *Campylobacter* infection, because such patients are also susceptible to a whole range of other pathogens. This is in sharp contrast to studies of patients with enhanced susceptibility to *Salmonella* and *Mycobacterium* spp., where "the human model" clearly points to specific host mechanisms that are involved in the defense against these pathogens (38, 128).

Innate Immunity to *Campylobacter*

Upon ingestion, *Campylobacter* has to first pass the acidic environment of the stomach. This is clearly an effective barrier, since patients that use proton pump inhibitors are more susceptible to *Campylobacter* infection (51, 121). In the intestine, *Campylobacter* has evolved strategies to circumvent the induction of innate immunity. For instance, Toll-like receptor 5 (TLR5), the pattern recognition receptor for flagellin, is not stimulated by *Campylobacter* due to the structure of its flagellin (5, 175). Also, TLR9, the receptor for CpG dinucleotides, is not efficiently stimulated (49). However, mice deficient in MyD88, a crucial signaling molecule downstream of TLRs, have recently been shown to be susceptible to *Campylobacter* infection (177), indicating that TLR pathways are important for the defense against disease. This is confirmed by the fact that NF- κ B-regulated transcription is readily activated in in vitro models (88) and apparently necessary for defense, since NF- κ B-gene deleted mice display enhanced susceptibility to infection (63). So although *Campylobacter* can circumvent the activation of innate immunity via TLR5 and TLR9, innate immune mechanisms are essential for host defense. Recently, it was shown that innate responses to *Campylobacter* are at

least partly mediated by the intracellular pattern recognition receptor NOD1 (190) and that natural resistance-associated macrophage protein, a gene involved in macrophage activation, also plays a role in susceptibility to campylobacteriosis (177).

Fucosylated sugars present in breast milk were shown to inhibit the in vitro and in vivo binding of *Campylobacter* to the intestinal mucosa and inhibit diarrhea (28, 112, 143). In addition, *C. jejuni* is serum sensitive, highlighting the importance of complement-mediated killing (28). The role of PMN-mediated killing of opsonized bacteria was shown to be variable (133). As discussed below (see "In Vitro Models of Infection"), a wide range of studies have shown that *Campylobacter* is able to induce a proinflammatory response. Whether a strong proinflammatory response is also induced in vivo is still under study.

Humoral Immunity to *Campylobacter*

Most people infected with *Campylobacter* develop humoral responses to a number of *Campylobacter* antigens. Experimental studies have shown the specificities and kinetics of immune responses during infection of primates and human volunteers (24, 145). In humans, circulating antibodies are first detectable 6 to 7 days after the onset of illness and rise rapidly shortly afterwards (reviewed in reference 124). Specific serum immunoglobulin A (IgA) levels peak 7 to 10 days after the onset of symptoms. Specific serum IgG levels peak after 3 to 4 weeks. Serum IgA levels decline rapidly after the onset of illness, whereas IgM and especially IgG levels remain high for a longer time (26, 40, 157). Antibody decay profiles for patients show that serum IgA levels declined to baseline levels within 2.5 months after infection (157), with a similar trend for salivary IgA levels (40). Serum and salivary IgG levels declined within 4.5 months after acute infection but remained elevated for prolonged periods of time, although large individual variation was apparent (40, 157). It is obviously more difficult to assess the kinetics of local, mucosal responses to infection, so there are fewer data on the subject. Specific antibodies have been detected in feces and urine during natural infection (99), and specific secretory IgA was detected in jejunal fluid from volunteer infections (24).

Antibody specificity studies have identified a number of *Campylobacter* antigens recognized during infection. Not surprisingly, many of the features highlighted as potential virulence factors, and which are on the cell surface, are immunogenic. A major, immunodominant antigen of *Campylobacter* is flagellin, the subunit protein of flagella (118, 119).

A number of other proteins, including major outer membrane proteins, have also been identified as being immunogenic, although their natures and roles are often unknown. The periplasmic/membrane-associated proteins PEB1 (28 kDa) and PEB3 (30 kDa) were found to be strongly immunogenic; 15/19 convalescent-phase sera were found to recognize them in enzyme-linked immunosorbent assays (132). Panigrahi et al. (129) identified a number of proteins that were expressed, or overexpressed, only in vivo. Two of these, with molecular masses of 47 and 84 kDa, were found to elicit strong serum IgG responses in humans following infection, including sera from volunteers who were immune to *C. jejuni* infection when re-challenged. Capsular polysaccharide antigens, the basis of the

Penner serotyping scheme, are also immunogenic, eliciting both type-specific and cross-reactive responses (114, 144). The CDT produced by *Campylobacter* is also immunogenic in human infections, eliciting toxin-neutralizing antibodies (1). Interestingly, chickens do not develop neutralizing antibodies against CDT, indicating host specificity in the immune response to *Campylobacter* (1). Until we know the true correlates of protective immunity to campylobacteriosis, the role of these antibodies in conferring protective immunity is difficult to establish.

Role of Humoral Immunity in Protection

As described above, epidemiological data indicate that humoral immunity is crucial for the development of protection against *Campylobacter* disease. Consistent with this, patients with defects in immunoglobulin production are more susceptible to infection. The first humoral immune mechanism encountered by *Campylobacter* during infection is secretory IgA (sIgA), and various studies have shown that the presence of *Campylobacter*-specific sIgA and serum IgA correlates with protection against disease (108, 142). Also, studies of breastfed infants point to a protective role of sIgA against infection. In a Mexican study where children were monitored from birth to the age of 2 years, breastfeeding decreased the incidence of diarrhea caused by *C. jejuni*, and this decrease was associated with the presence of *Campylobacter*-specific sIgA in breast milk (142). Breast milk containing sIgA against *Campylobacter* flagellin proteins also decreased the incidence of *Campylobacter*-induced diarrhea in babies. In addition, there is also a description of one immunocompromised patient in which oral sIgA administration resolved a recurrent *Campylobacter* infection (77).

Even though all these data point to an important role for sIgA in protection against *Campylobacter* disease, it is surprising that there are no studies to suggest that patients with IgA deficiency (35) are more susceptible to *Campylobacter* infection than the general population. IgA deficiency is the most common primary immunodeficiency found in humans, and it is estimated to occur at a frequency of 1:333 to 1:700 in Caucasians (46). The genetic cause underlying IgA deficiency is unknown, but from these data, it can be concluded that other compensatory mechanisms are activated in the absence of IgA and that IgA is probably important but not crucial for the host defense against *Campylobacter*. In addition, the presence of sIgA in a mother's breast milk is probably accompanied by the transplacental transfer of maternal IgG to the baby during pregnancy, indicating that effects observed in breastfeeding studies could also be related to IgG.

A protective role of IgM against *Campylobacter* infection was suggested by the observation that in hypo- or agammaglobulinemic patients who suffered from severe *Campylobacter* infection, the infusion of a pentaglobin preparation, which contained *Campylobacter*-specific IgM, completely resolved the infection, whereas immunoglobulin preparations that contained only IgG did not (31). Although this observation was made for a few of patients, it does point to a role for IgM in protection. This also fits with the assumption that increased IgM production is one of the general immune compensation mechanisms in patients with IgA deficiency. In addition, there

is an active secretion mechanism for IgM at mucosal surfaces (34), and IgM antibodies can fix complement almost 200 times more efficiently than IgG (32). In contrast to *Campylobacter*-specific IgG, IgM can also enhance reactive oxygen intermediate production and bactericidal activity of PMN (10).

From the finding that patients with hypo- or agammaglobulinemia are more susceptible to *Campylobacter* infection, it is clear that IgG also plays an important role in protection against disease. IgG levels remain high for a longer time than do IgA and IgM levels after infection (40, 157). Chronic raw milk consumers have high IgG levels and seem to be protected against *Campylobacter* disease (27). Similarly, children in developing countries develop IgG responses very early in life and are then protected against bloody diarrhea (25, 30), indicating that IgG is also involved in protection against disease.

Cellular Immunity

Systemic and recurrent *Campylobacter* infections in patients with human immunodeficiency virus or AIDS, who have a significant reduction in the level of CD4⁺ T cells, point to an important role of cell-mediated immunity in the defense against *Campylobacter* infection, although B-cell responses and antibody production can also be impaired in AIDS patients. There has been one report on the cellular immunity of a patient who suffered from severe *Campylobacter* infection. Peripheral blood mononuclear cells of this patient proliferated in response to the homologous strain (19). In addition, the rapid induction of proinflammatory cytokine production was observed in the serum of this patient. Recently, both viable and killed *Campylobacter* preparations were shown to induce the maturation of dendritic cells in vitro and the induction of various proinflammatory cytokines (83), indicating that *Campylobacter* induces both innate and specific cell-mediated immune responses.

There are also indications that *Campylobacter* extracts induce the in vitro expansion of γ/δ T cells obtained from healthy controls. This cell type has been implicated in mucosal immune responses. These cells respond to nonprotein components in the *Campylobacter* extract (168). Since it is not known whether γ/δ T-cell expansion also occurs in vivo, the significance of this observation in relation to protection against *Campylobacter* infection is unknown.

Although cell-mediated immunity appears to be important in the defense against *Campylobacter*, the available data do not point to specific candidate host factors that could be studied in humans.

LESSONS LEARNED FROM EXPERIMENTAL INFECTION

In Vitro Models of Infection

Study of the mechanisms of *Campylobacter* infection and pathogenesis is complicated by the lack of simple animal models that mimic human infection. In vitro cell culture methods provide a useful alternative to investigate the interactions between *Campylobacter* and the host epithelium that occur during infection. In the genomics era, there is an increasing use of in vitro cell culture techniques to determine the potential role of different genes in infection and pathogenesis. In vitro stud-

ies on host-pathogen interactions often use cells of epithelial origin. These can be nonpolarized (HeLa, HEp-2, and INT407) or polarized (Caco-2, HT29, and T84) cells. Polarized cell lines have an apical surface facing the luminal side and a basolateral side interfacing with the lamina propria and mimic the *in vivo* situation. Both sides differ biochemically with respect to transport functions and cellular localization of surface components such as TLRs (11, 72, 130). The use of polarized models is useful for studying microbial effects on transport, transcytosis mechanisms, and cell invasion (113). Nonpolarized models can also be used for studying bacterial virulence. Such studies have elucidated receptors, signaling pathways, and internalization mechanisms (55, 59, 96).

Invasion assays using *in vitro* cell culture models allow many parameters to be independently adjusted to achieve optimal results. Incubation time and assay volume, which can affect the results, are standard variables, while the number of internalized bacteria strongly depends on the type of cell line and *Campylobacter* strain used, the number of bacteria added per cell, and the concentration of antibiotics used to kill noninternalized bacteria (65). Although the mechanism of invasion is currently being unraveled, the fate of internalized *Campylobacter*, and whether they are able to replicate intracellularly, is still unknown (for a recent review, see reference 184). More recently, it was shown that *Campylobacter* was able to prevent targeting to lysosomes in epithelial cells, whereas it was targeted to lysosomes and rapidly killed by macrophages (176). These data indicate that the invasive properties of various *Campylobacter* strains are not fully understood. They also show a considerable range in invasive abilities among strains. However, evidence on the *in vitro* invasive ability of a strain and the development of disease symptoms (bacteremic/bloody diarrhea, etc.) has been conflicting (48, 60, 94, 120, 123) (see also <http://www.medvetnet.org/pdf/Reports/Workpackage8.pdf>), and some of the observed correlations may have been due to *in vivo* passage and not virulence properties per se (123). The toxicity of various strains has also been studied in cell culture systems, and those studies revealed that *Campylobacter*-induced toxicity varies from strain to strain (reviewed in reference 173).

Several studies have investigated host cell cytokine and chemokine responses to *Campylobacter* infection in cell culture models using human epithelial or macrophage cell lines. A number of studies showed that *Campylobacter* induces proinflammatory cytokines such as interleukin-8 (IL-8), IL-1, and tumor necrosis factor and chemokines such as CCL2 and CCL4 (2, 14, 88, 104). In addition, the production of Th1 cytokine gamma interferon, regulatory cytokine IL-10, and Th2 cytokine IL-4 has been observed (2). These responses appear to be dependent on NF- κ B and AP-1 activation (84, 88), although one study suggested NF- κ B-independent activation of proinflammatory cytokine production (88). Interestingly, viable *Campylobacter* cells are more potent at inducing proinflammatory cytokines than bacterial sonicates or supernatants (2, 14), suggesting that an active *Campylobacter* process is involved in these responses. Consistent with this, *Campylobacter* mutants with a reduced ability to adhere to epithelial cells are less potent inducers of proinflammatory responses (82). Furthermore, *Campylobacter*-induced IL-8 production is dependent on *de novo* protein synthesis (82, 175).

Animal Models of Infection

Murine models with defined deletions in components of innate or adaptive immunity are crucial in identifying genetic factors involved in the host defense against infection. However, progress in our understanding of *Campylobacter* infection and disease has been seriously hampered by the lack of an appropriate animal model, which makes studies in the above-mentioned gene-deleted mice impossible. Whereas most animals can be colonized with *Campylobacter*, gastroenteritis does not occur (reviewed in reference 122). Mice are not naturally colonized with *Campylobacter*, but in an experimental setting, colonization can be established. *Campylobacter* vaccination experiments have also been performed using such models, and protection against colonization with a homologous strain could be induced. Some authors have been able to induce gastrointestinal disease in infant mice (90). In these mice, intraperitoneal injection with *C. jejuni* produced self-limiting diarrhea, but since infant mice do not have a fully developed immune system, they are not suitable for studying "normal" *Campylobacter* disease or vaccine-induced protection. Also, in athymic, germ-free, nude mice, transient diarrhea was observed (186). Because these models display severe defects in the capacity to raise innate and adaptive immunity, they are not suitable for measuring immune responses to *Campylobacter*. For that reason, an intranasal challenge model in mice has been developed (16). Although this is not the natural infection route, intranasal infection of mice with *Campylobacter* results in systemic disease and death of a high proportion of mice. Various clinical isolates were differentially virulent in this model, and also, vaccine-induced protection could be measured. However, as no diarrhea has been reported, the relevance of this model for human disease is debatable, and extensive follow-up studies have not been performed.

More recently, it was shown that NF- κ B-deficient mice, which have a defect in the induction of the production of proinflammatory cytokines such as tumor necrosis factor alpha, IL-12, IL-1, and IL-6, develop gastroenteritis when infected with *Campylobacter* (63). Recently, two novel murine *Campylobacter* models were described, one using IL-10 gene-deleted mice (106) and one using MyD88 gene-deleted mice (177). The latter model, which is again a model of severely immunocompromised mice, also revealed a role for the gene encoding natural resistance-associated macrophage protein in determining resistance to campylobacteriosis, suggesting that in this model, macrophage activation and intracellular survival may contribute to pathology (177).

Diarrheal disease in young weanling ferrets (20, 62) and in some nonhuman primates (145) has been reported, although few laboratories have the facilities to maintain these models. A removable intestinal tie adult rabbit diarrhea model was also reported (185). The model involves surgery and is of questionable relevance to human disease, so it has not been used extensively. Although these models can shed light on the virulence of *Campylobacter* and the pathogenesis of the disease, they do not contribute to our understanding of the host factors involved in determining susceptibility to infection. In addition, ferret models may be complicated by the fact that ferrets are often fed on chicks and, as a result, could be relatively resistant to *Campylobacter* infection. A New World monkey *Aotus nan-*

cymae model was recently reported (87), which, if it proved to be reproducible in different laboratories and was able to demonstrate colonization and invasive differences among strains, could help to improve our understanding of *C. jejuni* virulence properties and the interaction of the organism with the host.

A large amount of work has been done using chicken models of infection. The avian gut is considered to be the natural environment of *C. jejuni*. Although disease has been reported (144), the organism is generally regarded as being a commensal pathogen. Therefore, although inappropriate for determining pathogenesis mechanisms, the chicken is a suitable model for determining colonization factors and in vivo survival mechanisms of thermophilic campylobacters (42). Furthermore, as the reduction of *C. jejuni* numbers in poultry is seen as a way to reduce the number of human cases (125), there have been a number of published reports focusing on avian host factors. Studies have characterized antibody responses to infection (39), and in vitro studies using avian cells have identified cell-mediated immune responses (154). Such studies have shown that maternally derived antibodies can protect against colonization (146) and identified a genetic basis for susceptibility to colonization (33). Those studies highlight the importance of host factors in determining the outcome of infection. Furthermore, comparison of responses among hosts with different pathologies and patterns of colonization can help to elucidate pathogenesis and virulence mechanisms of the bacterium and so aid in the development of control strategies.

Consistent with observations of patients, these studies show that severe immune defects in mice also led to enhanced susceptibility to infection. However, research using animal models has not yet led to the identification of clearly defined, specific immune mechanisms that are crucial for the host defense against *Campylobacter*. The recent progress in gene-deleted mice holds promise for future studies.

Human Volunteer Studies

With the lack of an appropriate animal model for *Campylobacter* infection, infection of human volunteers has been important in increasing our understanding of colonization and disease induction. These studies have shown that there is a clear dose-response relation between the number of ingested bacteria and colonization of the patients and that *Campylobacter* is highly infectious (23, 24). Surprisingly, no clear dose-response relation between the number of ingested bacteria and the development of clinical disease could be demonstrated in these studies. This is in sharp contrast to the data from a raw-milk outbreak, which showed a clear dose response, in presumably immunologically naïve children (159). However, the volunteers in this study were not screened for preexisting immunity to *Campylobacter*, and this, together with the small study groups, may (partially) explain this finding. The two *Campylobacter* strains used in these studies induced disease with different severities, indicating that not all *Campylobacter* strains have similar disease-inducing properties. After the volunteers recovered, some of them were challenged with the homologous strain, and it appeared that primary infection resulted in protection against disease but not against colonization. These data indicate that vaccination against *Campy-*

lobacter may be feasible, although the high level of variation among *Campylobacter* strains may hamper this approach.

VACCINE-INDUCED PROTECTION

Currently, there is no vaccine against campylobacteriosis available, but vaccination seems to be a good way to increase basal immunity in the population. Several approaches are followed: the development of (i) live attenuated vaccines, (ii) vaccines based on heat-killed/formalin-killed bacteria with or without mucosal adjuvants, (iii) subunit vaccines delivered together with adjuvants, and (iv) live attenuated *Salmonella* strains expressing *Campylobacter* proteins. For example, *recA* mutants that could be used as live attenuated vaccines have been developed (76). Formalin- or heat-killed bacterial preparations or combinations of the two have been used as oral vaccines, with or without *E. coli* heat-labile toxin to enhance mucosal responses. Such vaccine preparations were shown to induce protective immunity in mice, ferrets, and nonhuman primates (15, 17, 36, 141). Subunit vaccines based on FlaA were shown to induce short-term protective immunity in mice (100), and proteomics approaches are currently being used to identify *Campylobacter* surface proteins that could be included in subunit vaccines (137). Finally, an attenuated *Salmonella* vaccine expressing *Campylobacter* PEB1 was shown to induce humoral immunity in mice, with high seroconversion rates (90% to 100%), although these responses were not protective (150). Because of the link between *Campylobacter* infection and GBS, whole-cell vaccine approaches are seriously hampered. Both live and killed vaccine preparations should be based on *Campylobacter* strains that cannot induce GBS. A small study with volunteers has shown that none of the volunteers infected with virulent *Campylobacter* strains or with a killed vaccine preparation developed persistent antiganglioside antibodies (135). However, until we know exactly which bacterial and host properties are involved in the development of GBS, large-scale vaccine trials with whole-cell vaccines are probably not feasible.

FUTURE DIRECTIONS

What can we learn from all available information? All data described above clearly indicate that an effective immune system is crucial in the host defense against *Campylobacter* infection. However, which specific components of the host response are important is still largely unclear. In fact, there are many more open questions than clear answers. For instance, even though serological responses to *Campylobacter* infection have been studied and reveal that a good antibody response is essential, it is still not clear whether IgG, IgA, IgM, or combinations of the three are necessary.

Various approaches can be used to get answers to these basic questions. Murine models with defined deletions in components of innate or adaptive immunity, which have greatly aided the identification of genetic factors involved in the host defense against other pathogens, may yet be useful for our understanding of *Campylobacter* pathogenesis. Novel developments in such animal model systems may therefore open up possibilities for answering basic questions. Even though these models rely on the use of severely immunocompromised mice,

the transfer of sera and lymphocytes obtained after the infection of immunocompetent mice may be used to elucidate the immune mechanisms involved in protection against campylobacteriosis. Combined with measurement of both serum and saliva antibodies in human infections, this approach may shed light on this issue. This again highlights the importance of the development of protocols which can be followed when suspected outbreaks occur. Such naturally occurring events should be exploited more effectively to advance research into host-pathogen interactions in campylobacteriosis.

Another approach that could be taken is to perform human genetic studies. Infectious diseases have clearly posed a strong evolutionary pressure on the selection of immune genes. To what extent *Campylobacter* infection has also played a role in this process is unclear. Analysis of common polymorphisms in genes involved in gastric acid production, humoral immunity, innate immunity, and cell-mediated immunity could shed light on the roles of various processes in the defense against *Campylobacter* infection. However, it is also clear that it will not be so easy to select candidate genes for such studies.

A third approach that could be taken is to allow research into both host and pathogen factors to be much more driven by epidemiological findings. Age-related differences in acquiring infection with common and rare *Campylobacter* variants are an example of how this could be done. One could also envisage that similar studies can be performed with patients who do or do not use proton pump inhibitors. This may be used to elucidate whether enhanced susceptibility in these patients is related either to a higher effective dose or infection with less virulent strains. Also, the role of other identified risk factors for disease could be studied.

Finally, recent technical advances in host-pathogen interaction research now enable detailed molecular studies into the interaction of *Campylobacter* and the host. Large-scale microarray analysis can be performed either in vivo or in vitro, and the host response to *Campylobacter* infection can be analyzed in detail. Proteomics approaches to study host-pathogen interactions are also currently being developed. Such detailed molecular studies combined with better integration of host and pathogen research driven by epidemiological findings may truly advance our understanding of *Campylobacter* infection in humans.

ACKNOWLEDGMENTS

This review is presented on behalf of all members of Workpackage 30, whom we thank for their comments and support. Members of WP30 (alphabetically) are Thomas Alter, Dang Doung Bang, Shaun Cawthraw, Aurora Echeita, Steen Ethelberg, Rafal Gierczynski, Riny Janssen, Karen Krogfelt, Ida Luzzi, Jean-Yves Madec, Andy Lawson, Eva Moller Nielsen, Kare Molback, Noel McCarthy, Diane Newell, Robert Owen, Eva Olsson Engvall, Wilfrid van Pelt, Anne Ridley, Katell Rivoal, Fimme Jan van der Wal, and Jaap Wagenaar. We also thank Trudy Wassenaar, Arie Havelaar, Rob de Jonge, Barbara Hoebee, Sarah O'Brien, and Julian Ketley for critical comments.

This work was funded as an activity of Med-Vet-Net, a European Network of Excellence within the EU 6th Framework Programme.

REFERENCES

1. Abuoun, M., G. Manning, S. A. Cawthraw, A. Ridley, I. H. Ahmed, T. M. Wassenaar, and D. G. Newell. 2005. Cytolethal distending toxin (CDT)-negative *Campylobacter jejuni* strains and anti-CDT neutralizing antibodies are induced during human infection but not during colonization in chickens. *Infect. Immun.* **73**:3053–3062.
2. Al Salloom, F. S., A. Al Mahmeed, A. Ismaeel, G. A. Botta, and M. Bakhiet. 2003. *Campylobacter*-stimulated INT407 cells produce dissociated cytokine profiles. *J. Infect.* **47**:217–224.
3. Altekruse, S. F., N. J. Stern, P. I. Fields, and D. L. Swerdlow. 1999. *Campylobacter jejuni*—an emerging foodborne pathogen. *Emerg. Infect. Dis.* **5**:28–35.
4. Anders, B. J., B. A. Lauer, J. W. Paisley, and L. B. Reller. 1982. Double-blind placebo controlled trial of erythromycin for treatment of *Campylobacter* enteritis. *Lancet* **i**:131–132.
5. Andersen-Nissen, E., K. D. Smith, K. L. Strobe, S. L. Barrett, B. T. Cookson, S. M. Logan, and A. Aderem. 2005. Evasion of Toll-like receptor 5 by flagellated bacteria. *Proc. Natl. Acad. Sci. USA* **102**:9247–9252.
6. Ang, C. W., B. C. Jacobs, and J. D. Laman. 2004. The Guillain-Barre syndrome: a true case of molecular mimicry. *Trends Immunol.* **25**:61–66.
7. Ang, C. W., J. D. Laman, H. J. Willison, E. R. Wagner, H. P. Endtz, M. A. De Klerk, A. P. Tio-Gillen, N. Van den Braak, B. C. Jacobs, and P. A. van Doorn. 2002. Structure of *Campylobacter jejuni* lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. *Infect. Immun.* **70**:1202–1208.
8. Angulo, F. J., and D. L. Swerdlow. 1995. Bacterial enteric infections in persons infected with human immunodeficiency virus. *Clin. Infect. Dis.* **21**(Suppl. 1):S84–S93.
9. Aspinall, G. O., A. G. McDonald, H. Pang, L. A. Kurjanczyk, and J. L. Penner. 1994. Lipopolysaccharides of *Campylobacter jejuni* serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barre syndrome. *Biochemistry* **33**:241–249.
10. Autenrieth, I. B., A. Schwarzkopf, J. H. Ewald, H. Karch, and R. Lissner. 1995. Bactericidal properties of *Campylobacter jejuni*-specific immunoglobulin M antibodies in commercial immunoglobulin preparations. *Antimicrob. Agents Chemother.* **39**:1965–1969.
11. Backhed, F., and M. Hornef. 2003. Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? *Microbes Infect.* **5**:951–959.
12. Baker, M., N. Wilson, R. Ikram, S. Chambers, P. Shoemack, and G. Cook. 2006. Regulation of chicken contamination is urgently needed to control New Zealand's serious campylobacteriosis epidemic. *N. Z. Med. J.* **119**:U2264.
13. Baker, M. G., E. Sneyd, and N. A. Wilson. 2007. Is the major increase in notified campylobacteriosis in New Zealand real? *Epidemiol. Infect.* **135**:163–170.
14. Bakhiet, M., F. S. Al Salloom, A. Qareiballa, K. Bindayna, I. Farid, and G. A. Botta. 2004. Induction of alpha and beta chemokines by intestinal epithelial cells stimulated with *Campylobacter jejuni*. *J. Infect.* **48**:236–244.
15. Baqar, S., L. A. Applebee, and A. L. Bourgeois. 1995. Immunogenicity and protective efficacy of a prototype *Campylobacter* killed whole-cell vaccine in mice. *Infect. Immun.* **63**:3731–3735.
16. Baqar, S., A. L. Bourgeois, L. A. Applebee, A. S. Mourad, M. T. Kleinosky, Z. Mohran, and J. R. Murphy. 1996. Murine intranasal challenge model for the study of *Campylobacter* pathogenesis and immunity. *Infect. Immun.* **64**:4933–4939.
17. Baqar, S., A. L. Bourgeois, P. J. Schultheiss, R. I. Walker, D. M. Rollins, R. L. Haberberger, and O. R. Pavlovskis. 1995. Safety and immunogenicity of a prototype oral whole-cell killed *Campylobacter* vaccine administered with a mucosal adjuvant in non-human primates. *Vaccine* **13**:22–28.
18. Baqar, S., N. D. Pacheco, and F. M. Rollwagen. 1993. Modulation of mucosal immunity against *Campylobacter jejuni* by orally administered cytokines. *Antimicrob. Agents Chemother.* **37**:2688–2692.
19. Baqar, S., B. Rice, L. Lee, A. L. Bourgeois, A. N. El Din, D. R. Tribble, G. P. Heresi, A. S. Mourad, and J. R. Murphy. 2001. *Campylobacter jejuni* enteritis. *Clin. Infect. Dis.* **33**:901–905.
20. Bell, J. A., and D. D. Manning. 1990. A domestic ferret model of immunity to *Campylobacter jejuni*-induced enteric disease. *Infect. Immun.* **58**:1848–1852.
21. Berberian, L. S., Y. Valles-Ayoub, L. K. Gordon, S. R. Targan, and J. Braun. 1994. Expression of a novel autoantibody defined by the VH3-15 gene in inflammatory bowel disease and *Campylobacter jejuni* enterocolitis. *J. Immunol.* **153**:3756–3763.
22. Berden, J. H., H. L. Muijtjens, and L. B. van de Putte. 1979. Reactive arthritis associated with *Campylobacter jejuni* enteritis. *Br. Med. J.* **i**:380–381.
23. Black, R. E., M. M. Levine, M. L. Clements, T. P. Hughes, and M. J. Blaser. 1988. Experimental *Campylobacter jejuni* infection in humans. *J. Infect. Dis.* **157**:472–479.
24. Black, R. E., D. M. Perlman, M. L. Clements, M. M. Levine, and M. J. Blaser. 1992. Human volunteer studies with *Campylobacter jejuni*, p. 207–215. In I. Nachamkin, M. J. Blaser, and L. S. Tompkins (ed.), *Campylobacter jejuni*: current status and future trends. ASM Press, Washington, DC.
25. Blaser, M. J., R. E. Black, D. J. Duncan, and J. Amer. 1985. *Campylobacter jejuni*-specific serum antibodies are elevated in healthy Bangladeshi children. *J. Clin. Microbiol.* **21**:164–167.
26. Blaser, M. J., and D. J. Duncan. 1984. Human serum antibody response to

- Campylobacter jejuni* infection as measured in an enzyme-linked immunosorbent assay. *Infect. Immun.* **44**:292–298.
27. Blaser, M. J., E. Sazie, and L. P. Williams, Jr. 1987. The influence of immunity on raw milk-associated *Campylobacter* infection. *JAMA* **257**: 43–46.
 28. Blaser, M. J., P. F. Smith, and P. F. Kohler. 1985. Susceptibility of *Campylobacter* isolates to the bactericidal activity of human serum. *J. Infect. Dis.* **151**:227–235.
 29. Reference deleted.
 30. Blaser, M. J., D. N. Taylor, and P. Echeverria. 1986. Immune response to *Campylobacter jejuni* in a rural community in Thailand. *J. Infect. Dis.* **153**:249–254.
 31. Borleffs, J. C., J. F. Schellekens, E. Brouwer, and M. Rozenberg-Arksa. 1993. Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent *Campylobacter jejuni* infection. *Eur. J. Clin. Microbiol. Infect. Dis.* **12**:772–775.
 32. Borsos, T., and H. J. Rapp. 1965. Complement fixation on cell surfaces by 19S and 7S antibodies. *Science* **150**:505–506.
 33. Boyd, Y., E. G. Herbert, K. L. Marston, M. A. Jones, and P. A. Barrow. 2005. Host genes affect intestinal colonisation of newly hatched chickens by *Campylobacter jejuni*. *Immunogenetics* **57**:248–253.
 34. Brandtzaeg, P. 1981. Transport models for secretory IgA and secretory IgM. *Clin. Exp. Immunol.* **44**:221–232.
 35. Brandtzaeg, P., D. E. Nilssen, T. O. Rognum, and P. S. Thrane. 1991. Ontogeny of the mucosal immune system and IgA deficiency. *Gastroenterol. Clin. N. Am.* **20**:397–439.
 36. Burr, D. H., D. Rollins, L. H. Lee, D. L. Pattarini, S. S. Walz, J. H. Tian, J. L. Pace, A. L. Bourgeois, and R. I. Walker. 2005. Prevention of disease in ferrets fed an inactivated whole cell *Campylobacter jejuni* vaccine. *Vaccine* **23**:4315–4321.
 37. Caporale, C. M., F. Papola, M. A. Fioroni, A. Aureli, A. Giovannini, F. Notturmo, D. Adorno, V. Caporale, and A. Uncini. 2006. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes. *J. Neuroimmunol.* **177**:112–118.
 38. Casanova, J. L., and L. Abel. 2002. Genetic dissection of immunity to mycobacteria: the human model. *Annu. Rev. Immunol.* **20**:581–620.
 39. Cawthraw, S., R. Ayling, P. Nuijten, T. Wassenaar, and D. G. Newell. 1994. Isotype, specificity, and kinetics of systemic and mucosal antibodies to *Campylobacter jejuni* antigens, including flagellin, during experimental oral infections of chickens. *Avian Dis.* **38**:341–349.
 40. Cawthraw, S. A., R. A. Feldman, A. R. Sayers, and D. G. Newell. 2002. Long-term antibody responses following human infection with *Campylobacter jejuni*. *Clin. Exp. Immunol.* **130**:101–106.
 41. Cawthraw, S. A., L. Lind, B. Kaijser, and D. G. Newell. 2000. Antibodies, directed towards *Campylobacter jejuni* antigens, in sera from poultry abattoir workers. *Clin. Exp. Immunol.* **122**:55–60.
 42. Cawthraw, S. A., S. Park, B. W. Wren, J. M. Ketley, R. Ayling, and D. G. Newell. 1996. The usefulness of the chick colonisation model to investigate potential colonisation factors of campylobacters, p. 649–652. *In* D. G. Newell, J. M. Ketley, and R. A. Feldman (ed.), *Campylobacter, Helicobacter and related organisms*. Plenum Press, New York, NY.
 43. Cawthraw, S. A., T. M. Wassenaar, R. Ayling, and D. G. Newell. 1996. Increased colonization potential of *Campylobacter jejuni* strain 81116 after passage through chickens and its implication on the rate of transmission within flocks. *Epidemiol. Infect.* **117**:213–215.
 44. Centers for Disease Control and Prevention. 2004. Preliminary FoodNet data on the incidence of infection with pathogens transmitted through food—selected sites, United States, 2003. *MMWR Morb. Mortal. Wkly. Rep.* **53**:338–343.
 45. Christenson, B., A. Ringner, C. Blucher, H. Billaudelle, K. N. Gundtoft, G. Eriksson, and M. Bottiger. 1983. An outbreak of campylobacter enteritis among the staff of a poultry abattoir in Sweden. *Scand. J. Infect. Dis.* **15**:167–172.
 46. Clark, J. A., P. A. Callicot, N. A. Brenner, C. A. Bradley, and D. M. Smith, Jr. 1983. Selective IgA deficiency in blood donors. *Am. J. Clin. Pathol.* **80**:210–213.
 47. Coker, A. O., R. D. Isokpehi, B. N. Thomas, K. O. Amisu, and C. L. Obi. 2002. Human campylobacteriosis in developing countries. *Emerg. Infect. Dis.* **8**:237–244.
 48. Coote, J. G., D. E. Stewart-Tull, R. J. Owen, F. J. Bolton, B. L. Siemer, D. Candlish, D. H. Thompson, A. C. Wardlaw, S. L. On, A. Candlish, B. Billcliffe, P. J. Jordan, K. Kristiansen, and P. Borman. 2007. Comparison of virulence-associated *in vitro* properties of typed strains of *Campylobacter jejuni* from different sources. *J. Med. Microbiol.* **56**:722–732.
 49. Dalpke, A., J. Frank, M. Peter, and K. Heeg. 2006. Activation of Toll-like receptor 9 by DNA from different bacterial species. *Infect. Immun.* **74**:940–946.
 50. Doorduyn, Y., W. E. Van Den Brandhof, Y. T. van Duynhoven, W. J. Wannet, and W. Van Pelt. 2006. Risk factors for *Salmonella* Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. *Epidemiol. Infect.* **134**:617–626.
 51. Doorduyn, Y., W. Van Pelt, C. L. Siezen, F. van der Horst, Y. T. van Duynhoven, B. Hoebee, and R. Janssen. 2007. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. *Epidemiol. Infect.* [Epub ahead of print.] doi:10.1017/S095026880700996X.
 52. Dunlop, S. P., D. Jenkins, K. R. Neal, and R. C. Spiller. 2003. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. *Gastroenterology* **125**:1651–1659.
 53. Eastmond, C. J., J. A. Rennie, and T. M. Reid. 1983. An outbreak of *Campylobacter* enteritis—a rheumatological followup survey. *J. Rheumatol.* **10**:107–108.
 54. EFSA. 2006. The community summary report on trends and sources of zoonoses, zoonotic agents, antimicrobial resistance and foodborne outbreaks in the European Union in 2005. *EFSA J.* **94**:1–236.
 55. Elsinghorst, E. A. 1994. Measurement of invasion by gentamicin resistance. *Methods Enzymol.* **236**:405–420.
 56. Emonts, M., R. H. Veenhoven, S. P. Wiertsema, J. J. Houwing-Duistermaat, V. Walraven, R. de Groot, P. W. Hermans, and E. A. Sanders. 2007. Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. *Pediatrics* **120**:814–823.
 57. Engberg, J., P. Gerner-Smidt, F. Scheutz, N. E. Moller, S. L. On, and K. Molbak. 1998. Water-borne *Campylobacter jejuni* infection in a Danish town—a 6-week continuous source outbreak. *Clin. Microbiol. Infect.* **4**:648–656.
 58. Ethelberg, S., J. Simonsen, P. Gerner-Smidt, K. E. Olsen, and K. Molbak. 2005. Spatial distribution and registry-based case-control analysis of *Campylobacter* infections in Denmark, 1991–2001. *Am. J. Epidemiol.* **162**: 1008–1015.
 59. Everest, P. H., H. Goossens, J. P. Butzler, D. Lloyd, S. Knutton, J. M. Ketley, and P. H. Williams. 1992. Differentiated Caco-2 cells as a model for enteric invasion by *Campylobacter jejuni* and *C. coli*. *J. Med. Microbiol.* **37**:319–325.
 60. Fauchere, J. L., A. Rosenau, M. Veron, E. N. Moya, S. Richard, and A. Pfister. 1986. Association with HeLa cells of *Campylobacter jejuni* and *Campylobacter coli* isolated from human feces. *Infect. Immun.* **54**:283–287.
 61. Fischer, A. 2004. Human primary immunodeficiency diseases: a perspective. *Nat. Immunol.* **5**:23–30.
 62. Fox, J. G., J. I. Ackerman, N. Taylor, M. Claps, and J. C. Murphy. 1987. *Campylobacter jejuni* infection in the ferret: an animal model of human campylobacteriosis. *Am. J. Vet. Res.* **48**:85–90.
 63. Fox, J. G., A. B. Rogers, M. T. Whary, Z. Ge, N. S. Taylor, S. Xu, B. H. Horwitz, and S. E. Erdman. 2004. Gastroenteritis in NF- κ B-deficient mice is produced with wild-type *Campylobacter jejuni* but not with *C. jejuni* lacking cytolethal distending toxin despite persistent colonization with both strains. *Infect. Immun.* **72**:1116–1125.
 64. Friedman, C. R., J. Neimann, H. C. Wegener, and R. V. Tauxe. 2000. Epidemiology of *Campylobacter jejuni* infections in the United States and other industrialized nations, p. 121–139. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 65. Friis, L. M., C. Pin, B. M. Pearson, and J. M. Wells. 2005. *In vitro* cell culture methods for investigating *Campylobacter* invasion mechanisms. *J. Microbiol. Methods* **61**:145–160.
 66. Gauci, A., and A. Ammon. 2007. The First European Communicable Disease Epidemiological Report. European Centre of Disease Prevention and Control, Solna, Sweden.
 67. Geboes, K. 2001. Crohn's disease, ulcerative colitis or indeterminate colitis—how important is it to differentiate? *Acta Gastroenterol. Belg.* **64**:197–200.
 68. Geleijns, K., M. Emonts, J. D. Laman, W. van Rijs, P. A. van Doorn, P. W. Hermans, and B. C. Jacobs. 2007. Genetic polymorphisms of macrophage-mediators in Guillain-Barre syndrome. *J. Neuroimmunol.* **190**:127–130.
 69. Geleijns, K., B. C. Jacobs, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, and P. A. van Doorn. 2004. Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or *Campylobacter jejuni* infection in Guillain-Barre patients. *J. Neuroimmunol.* **150**:132–138.
 70. Geleijns, K., A. Roos, J. J. Houwing-Duistermaat, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, P. A. van Doorn, and B. C. Jacobs. 2006. Mannose-binding lectin contributes to the severity of Guillain-Barre syndrome. *J. Immunol.* **177**:4211–4217.
 71. Geleijns, K., G. M. Schreuder, B. C. Jacobs, K. Sintnicolaas, R. van Koningsveld, J. Meulstee, J. D. Laman, and P. A. van Doorn. 2005. HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. *Neurology* **64**:44–49.
 72. Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara. 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. *J. Immunol.* **167**:1882–1885.
 73. Godschalk, P. C., A. P. Heikema, M. Gilbert, T. Komagamine, C. W. Ang, J. Glerum, D. Brochu, J. Li, N. Yuki, B. C. Jacobs, A. van Belkum, and H. P. Endtz. 2004. The crucial role of *Campylobacter jejuni* genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. *J. Clin. Invest.* **114**:1659–1665.

74. Green, C. G., D. Krause, and J. Wylie. 2006. Spatial analysis of *Campylobacter* infection in the Canadian province of Manitoba. *Int. J. Health Geogr.* 5:2.
75. Grimbacher, B., A. Hutloff, M. Schlesier, E. Glocker, K. Warnatz, R. Drager, H. Eibel, B. Fischer, A. A. Schaffer, H. W. Mages, R. A. Kroczeck, and H. H. Peter. 2003. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. *Nat. Immunol.* 4:261–268.
76. Guerry, P., P. M. Pope, D. H. Burr, J. Leifer, S. W. Joseph, and A. L. Bourgeois. 1994. Development and characterization of *recA* mutants of *Campylobacter jejuni* for inclusion in attenuated vaccines. *Infect. Immun.* 62:426–432.
77. Hammarstrom, V., C. I. Smith, and L. Hammarstrom. 1993. Oral immunoglobulin treatment in *Campylobacter jejuni* enteritis. *Lancet* 341:1036.
78. Hannu, T., L. Mattila, H. Rautelin, P. Pelkonen, P. Lahdenne, A. Siitonen, and M. Leirisalo-Repo. 2002. *Campylobacter*-triggered reactive arthritis: a population-based study. *Rheumatology (Oxford)* 41:312–318.
79. Havelaar, A. H., M. A. de Wit, R. van Koningsveld, and E. van Kempen. 2000. Health burden in The Netherlands due to infection with thermophilic *Campylobacter* spp. *Epidemiol. Infect.* 125:505–522.
80. Havelaar, A. H., M. Nauta, M. J. Manges, E. Katsma, M. J. Boogaardt, J. Wagenaar, and the CARMA Projectgroep. 2005. Kosten en baten van *Campylobacter* bestrijding-integratie van risico-analyse, epidemiologie en economie. RIVM report 250911008. RIVM, Bilthoven, The Netherlands.
81. Helms, M., J. Simonsen, and K. Molbak. 2006. Foodborne bacterial infection and hospitalization: a registry-based study. *Clin. Infect. Dis.* 42:498–506.
82. Hickey, T. E., S. Baqar, A. L. Bourgeois, C. P. Ewing, and P. Guerry. 1999. *Campylobacter jejuni*-stimulated secretion of interleukin-8 by INT407 cells. *Infect. Immun.* 67:88–93.
83. Hu, L., M. D. Bray, M. Osorio, and D. J. Kopecko. 2006. *Campylobacter jejuni* induces maturation and cytokine production in human dendritic cells. *Infect. Immun.* 74:2697–2705.
84. Hu, L., and T. E. Hickey. 2005. *Campylobacter jejuni* induces secretion of proinflammatory chemokines from human intestinal epithelial cells. *Infect. Immun.* 73:4437–4440.
85. Hu, L., and D. J. Kopecko. 2000. Interactions of *Campylobacter* with eukaryotic cells: gut luminal colonization and mucosal invasion mechanisms, p. 191–215. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM, Washington, DC.
86. Hughes, R. A., and D. R. Cornblath. 2005. Guillain-Barre syndrome. *Lancet* 366:1653–1666.
87. Jones, F. R., S. Baqar, A. Gozalo, G. Nunez, N. Espinoza, S. M. Reyes, M. Salazar, R. Meza, C. K. Porter, and S. E. Walz. 2006. New World monkey *Aotus nancymae* as a model for *Campylobacter jejuni* infection and immunity. *Infect. Immun.* 74:790–793.
88. Jones, M. A., S. Totemeyer, D. J. Maskell, C. E. Bryant, and P. A. Barrow. 2003. Induction of proinflammatory responses in the human monocytic cell line THP-1 by *Campylobacter jejuni*. *Infect. Immun.* 71:2626–2633.
89. Kapperud, G., J. Lassen, S. M. Ostroff, and S. Aasen. 1992. Clinical features of sporadic *Campylobacter* infections in Norway. *Scand. J. Infect. Dis.* 24:741–749.
90. Kazmi, S. U., B. S. Roberson, and N. J. Stern. 1984. Animal-passed, virulence-enhanced *Campylobacter jejuni* causes enteritis in neonatal mice. *Curr. Microbiol.* 11:159–164.
91. Keat, A., and I. Rowe. 1991. Reiter's syndrome and associated arthritides. *Rheum. Dis. Clin. N. Am.* 17:25–42.
92. Kemmeren, J. M., M. J. Manges, Y. T. van Duynhoven, and A. H. Havelaar. 2005. Priority setting of foodborne pathogens. RIVM report 330080001. RIVM, Bilthoven, The Netherlands.
93. Kist, M. 2002. Impact and management of *Campylobacter* in human medicine—European perspective. *Int. J. Infect. Dis.* 6:S44–S47.
94. Klipstein, F. A., R. F. Engert, H. Short, and E. A. Schenk. 1985. Pathogenic properties of *Campylobacter jejuni*: assay and correlation with clinical manifestations. *Infect. Immun.* 50:43–49.
95. Koga, M., N. Yuki, K. Kashiwase, K. Tadokoro, T. Juji, and K. Hirata. 1998. Guillain-Barre and Fisher's syndromes subsequent to *Campylobacter jejuni* enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. *J. Neuroimmunol.* 88:62–66.
96. Krause-Gruszczynska, M., M. Rohde, R. Hartig, H. Genth, G. Schmidt, T. Keo, W. Konig, W. G. Miller, M. E. Konkel, and S. Backert. 2007. Role of the small Rho GTPases Rac1 and Cdc42 in host cell invasion of *Campylobacter jejuni*. *Cell. Microbiol.* 9:2431–2444.
97. Kuroki, S., T. Saida, M. Nukina, T. Haruta, M. Yoshioka, Y. Kobayashi, and H. Nakanishi. 1993. *Campylobacter jejuni* strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. *Ann. Neurol.* 33:243–247.
98. Kuusi, M., J. P. Nuorti, M. L. Hanninen, M. Koskela, V. Jussila, E. Kela, I. Miettinen, and P. Ruutu. 2005. A large outbreak of campylobacteriosis associated with a municipal water supply in Finland. *Epidemiol. Infect.* 133:593–601.
99. Lane, E. M., R. A. Batchelor, A. L. Bourgeois, D. H. Burr, and J. G. Olson. 1987. Urine and faecal IgA response during naturally acquired infection with *Campylobacter jejuni*. *Lancet* i:1141.
100. Lee, L. H., E. Burg III, S. Baqar, A. L. Bourgeois, D. H. Burr, C. P. Ewing, T. J. Trust, and P. Guerry. 1999. Evaluation of a truncated recombinant flagellin subunit vaccine against *Campylobacter jejuni*. *Infect. Immun.* 67:5799–5805.
101. Locht, H., and K. A. Krogh. 2002. Comparison of rheumatological and gastrointestinal symptoms after infection with *Campylobacter coli* and enterotoxigenic *Escherichia coli*. *Ann. Rheum. Dis.* 61:448–452.
102. Ma, J. J., M. Nishimura, H. Mine, S. Kuroki, M. Nukina, M. Ohta, H. Saji, H. Obayashi, H. Kawakami, T. Saida, and T. Uchiyama. 1998. Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome. *Ann. Neurol.* 44:815–818.
103. Ma, J. J., M. Nishimura, H. Mine, S. Kuroki, M. Nukina, M. Ohta, H. Saji, H. Obayashi, T. Saida, H. Kawakami, and T. Uchiyama. 1998. HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. *Neurology* 51:379–384.
104. MacCallum, A. J., D. Harris, G. Haddock, and P. H. Everest. 2006. *Campylobacter jejuni*-infected human epithelial cell lines vary in their ability to secrete interleukin-8 compared to in vitro-infected primary human intestinal tissue. *Microbiology* 152:3661–3665.
105. Mandal, B. K., M. E. Ellis, E. M. Dunbar, and K. Whale. 1984. Double-blind placebo-controlled trial of erythromycin in the treatment of clinical campylobacter infection. *J. Antimicrob. Chemother.* 13:619–623.
106. Mansfield, L. S., J. A. Bell, D. L. Wilson, A. J. Murphy, H. M. Elsheikha, V. A. Rathinam, B. R. Fierro, J. E. Linz, and V. B. Young. 2007. C57BL/6 and congenic interleukin-10-deficient mice can serve as models of *Campylobacter jejuni* colonization and enteritis. *Infect. Immun.* 75:1099–1115.
107. Martin, P. M., J. Mathiot, J. Ipero, M. Kirimat, A. J. Georges, and M. C. Georges-Courbot. 1989. Immune response to *Campylobacter jejuni* and *Campylobacter coli* in a cohort of children from birth to 2 years of age. *Infect. Immun.* 57:2542–2546.
108. Megraud, F., G. Boudraa, K. Bessaoud, S. Bensid, F. Dabis, R. Soltana, and M. Touhami. 1990. Incidence of *Campylobacter* infection in infants in western Algeria and the possible protective role of breast feeding. *Epidemiol. Infect.* 105:73–78.
109. Melby, K., O. P. Dahl, L. Crisp, and J. L. Penner. 1990. Clinical and serological manifestations in patients during a waterborne epidemic due to *Campylobacter jejuni*. *J. Infect.* 21:309–316.
110. Miller, G., G. M. Dunn, T. M. Reid, I. D. Ogden, and N. J. Strachan. 2005. Does age acquired immunity confer selective protection to common serotypes of *Campylobacter jejuni*? *BMC Infect. Dis.* 5:66.
111. Millson, M., M. Bokhout, J. Carlson, L. Spielberg, R. Aldis, A. Borczyk, and H. Lior. 1991. An outbreak of *Campylobacter jejuni* gastroenteritis linked to meltwater contamination of a municipal well. *Can. J. Public Health* 82:27–31.
112. Morrow, A. L., G. M. Ruiz-Palacios, M. Altaye, X. Jiang, M. L. Guerrero, J. K. Meinen-Derr, T. Farkas, P. Chaturvedi, L. K. Pickering, and D. S. Newburg. 2004. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. *J. Pediatr.* 145:297–303.
113. Mostov, K. E., M. Verges, and Y. Altschuler. 2000. Membrane traffic in polarized epithelial cells. *Curr. Opin. Cell Biol.* 12:483–490.
114. Moura, A. C., and M. Mariano. 1997. Lipids from *Mycobacterium leprae* cell wall suppress T-cell activation in vivo and in vitro. *Immunology* 92:429–436.
115. Myhr, K. M., K. S. Vagnes, T. H. Maroy, J. H. Aarseth, H. I. Nyland, and C. A. Vedeler. 2003. Interleukin-10 promoter polymorphisms in patients with Guillain-Barre syndrome. *J. Neuroimmunol.* 139:81–83.
116. Nachamkin, I., B. M. Allos, and T. W. Ho. 2000. *Campylobacter jejuni* infection and the association with Guillain-Barre syndrome, p. 155–178. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
117. Nachamkin, I., H. Ung, A. P. Moran, D. Yoo, M. M. Prendergast, M. A. Nicholson, K. Sheikh, T. Ho, A. K. Asbury, G. M. McKhann, and J. W. Griffin. 1999. Ganglioside GM1 mimicry in *Campylobacter* strains from sporadic infections in the United States. *J. Infect. Dis.* 179:1183–1189.
118. Nachamkin, I., and X. H. Yang. 1989. Human antibody response to *Campylobacter jejuni* flagellin protein and a synthetic N-terminal flagellin peptide. *J. Clin. Microbiol.* 27:2195–2198.
119. Nachamkin, I., and X. H. Yang. 1992. Local immune responses to the *Campylobacter* flagellin in acute *Campylobacter* gastrointestinal infection. *J. Clin. Microbiol.* 30:509–511.
120. Nadeau, E., S. Messier, and S. Quessy. 2003. Comparison of *Campylobacter* isolates from poultry and humans: association between in vitro virulence properties, biotypes, and pulsed-field gel electrophoresis clusters. *Appl. Environ. Microbiol.* 69:6316–6320.
121. Neal, K. R., H. M. Scott, R. C. Slack, and R. F. Logan. 1996. Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study. *BMJ* 312:414–415.
122. Newell, D. G. 2001. Animal models of *Campylobacter jejuni* colonization and disease and the lessons to be learned from similar *Helicobacter pylori* models. *Symp. Ser. Soc. Appl. Microbiol.* 2001:57S–67S.
123. Newell, D. G., H. McBride, F. Saunders, Y. Dehele, and A. D. Pearson. 1985.

- The virulence of clinical and environmental isolates of *Campylobacter jejuni*. *J. Hyg. (London)* **94**:45–54.
124. **Newell, D. G., and I. Nachamkin.** 1992. Immune responses directed against *Campylobacter jejuni*, p. 201–206. In I. Nachamkin, M. J. Blaser, and L. S. Tompkins (ed.), *Campylobacter jejuni: current status and future trends*. ASM Press, Washington, DC.
 125. **Newell, D. G., and J. A. Wagenaar.** 2000. Poultry infections and their control at farm level, p. 497–509. In I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 126. **Nolan, C. M., K. E. Johnson, M. B. Coyle, and K. Faler.** 1983. *Campylobacter jejuni* enteritis: efficacy of antimicrobial and antimotility drugs. *Am. J. Gastroenterol.* **78**:621–626.
 127. **Oberhelman, R. A., and D. N. Taylor.** 2000. *Campylobacter* infections in developing countries, p. 139–154. In I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 128. **Ottenhoff, T. H., F. A. Verreck, E. G. Lichtenauer-Kaligis, M. A. Hoeve, O. Sanal, and J. T. van Dissel.** 2002. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. *Nat. Genet.* **32**:97–105.
 129. **Panigrahi, P., G. Losonsky, L. J. DeTolla, and J. G. Morris, Jr.** 1992. Human immune response to *Campylobacter jejuni* proteins expressed in vivo. *Infect. Immun.* **60**:4938–4944.
 130. **Parkhill, J., B. W. Wren, K. Mungall, J. M. Ketley, C. Churcher, D. Basham, T. Chillingworth, R. M. Davies, T. Feltwell, S. Holroyd, K. Jagels, A. V. Karlyshev, S. Moule, M. J. Pallen, C. W. Penn, M. A. Quail, M. A. Rajandream, K. M. Rutherford, A. H. van Vliet, S. Whitehead, and B. G. Barrell.** 2000. The genome sequence of the food-borne pathogen *Campylobacter jejuni* reveals hypervariable sequences. *Nature* **403**:665–668.
 131. **Pazzaglia, G., A. L. Bourgeois, K. el Diwany, N. Nour, N. Badran, and R. Hablas.** 1991. *Campylobacter* diarrhoea and an association of recent disease with asymptomatic shedding in Egyptian children. *Epidemiol. Infect.* **106**:77–82.
 132. **Pei, Z. H., R. T. Ellison III, and M. J. Blaser.** 1991. Identification, purification, and characterization of major antigenic proteins of *Campylobacter jejuni*. *J. Biol. Chem.* **266**:16363–16369.
 133. **Pennie, R. A., R. D. Pearson, L. J. Barrett, H. Lior, and R. L. Guerrant.** 1986. Susceptibility of *Campylobacter jejuni* to strain-specific bactericidal activity in sera of infected patients. *Infect. Immun.* **52**:702–706.
 134. **Perlman, D. M., N. M. Ampel, R. B. Schiffman, D. L. Cohn, C. M. Patton, M. L. Aguirre, W. L. Wang, and M. J. Blaser.** 1988. Persistent *Campylobacter jejuni* infections in patients infected with the human immunodeficiency virus (HIV). *Ann. Intern. Med.* **108**:540–546.
 135. **Prendergast, M. M., D. R. Tribble, S. Baqar, D. A. Scott, J. A. Ferris, R. I. Walker, and A. P. Moran.** 2004. In vivo phase variation and serologic response to lipooligosaccharide of *Campylobacter jejuni* in experimental human infection. *Infect. Immun.* **72**:916–922.
 136. **Pritchard, J., R. A. Hughes, J. H. Rees, H. J. Willison, and J. A. Nicoll.** 2003. Apolipoprotein E genotypes and clinical outcome in Guillain-Barre syndrome. *J. Neurol. Neurosurg. Psychiatry* **74**:971–973.
 137. **Prokhorova, T. A., P. N. Nielsen, J. Petersen, T. Kofoed, J. S. Crawford, C. Morscheck, A. Boysen, and P. Schrotz-King.** 2006. Novel surface polypeptides of *Campylobacter jejuni* as traveller's diarrhoea vaccine candidates discovered by proteomics. *Vaccine* **24**:6446–6455.
 138. **Rees, J. H., S. E. Soudain, N. A. Gregson, and R. A. Hughes.** 1995. *Campylobacter jejuni* infection and Guillain-Barre syndrome. *N. Engl. J. Med.* **333**:1374–1379.
 139. **Richardson, G., D. R. Thomas, R. M. Smith, L. Nehaul, C. D. Ribeiro, A. G. Brown, and R. L. Salmon.** 2007. A community outbreak of *Campylobacter jejuni* infection from a chlorinated public water supply. *Epidemiol. Infect.* **135**:1151–1158.
 140. **Robinson, D. A.** 1981. Infective dose of *Campylobacter jejuni* in milk. *BMJ (Clin. Res. Ed.)* **282**:1584.
 141. **Rollwagen, F. M., N. D. Pacheco, J. D. Clements, O. Pavlovskis, D. M. Rollins, and R. I. Walker.** 1993. Killed *Campylobacter* elicits immune response and protection when administered with an oral adjuvant. *Vaccine* **11**:1316–1320.
 142. **Ruiz-Palacios, G. M., J. J. Calva, L. K. Pickering, Y. Lopez-Vidal, P. Volkow, H. Pezzarossi, and M. S. West.** 1990. Protection of breast-fed infants against *Campylobacter* diarrhea by antibodies in human milk. *J. Pediatr.* **116**:707–713.
 143. **Ruiz-Palacios, G. M., L. E. Cervantes, P. Ramos, B. Chavez-Munguia, and D. S. Newburg.** 2003. *Campylobacter jejuni* binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. *J. Biol. Chem.* **278**:14112–14120.
 144. **Ruiz-Palacios, G. M., E. Escamilla, and N. Torres.** 1981. Experimental *Campylobacter* diarrhea in chickens. *Infect. Immun.* **34**:250–255.
 145. **Russell, R. G., M. J. Blaser, J. I. Sarmiento, and J. Fox.** 1989. Experimental *Campylobacter jejuni* infection in *Macaca nemestrina*. *Infect. Immun.* **57**:1438–1444.
 146. **Sahin, O., N. Luo, S. Huang, and Q. Zhang.** 2003. Effect of *Campylobacter*-specific maternal antibodies on *Campylobacter jejuni* colonization in young chickens. *Appl. Environ. Microbiol.* **69**:5372–5379.
 147. **Salazar-Lindo, E., R. B. Sack, E. Chea-Woo, B. A. Kay, Z. A. Piscoya, R. Leon-Barua, and A. Yi.** 1986. Early treatment with erythromycin of *Campylobacter jejuni*-associated dysentery in children. *J. Pediatr.* **109**:355–360.
 148. **Samuel, M. C., D. J. Vugia, S. Shallow, R. Marcus, S. Segler, T. McGivern, H. Kassenborg, K. Reilly, M. Kennedy, F. Angulo, and R. V. Tauxe.** 2004. Epidemiology of sporadic *Campylobacter* infection in the United States and declining trend in incidence, FoodNet 1996–1999. *Clin. Infect. Dis.* **38**(Suppl. 3):S165–S174.
 149. **Schiellerup, P., K. A. Krogh, and H. Locht.** 2008. A comparison of self-reported joint symptoms following infection with different enteric pathogens: effect of HLA-B27. *J. Rheumatol.* **35**:480–487.
 150. **Sizemore, D. R., B. Warner, J. Lawrence, A. Jones, and K. P. Killeen.** 2006. Live, attenuated *Salmonella typhimurium* vectoring *Campylobacter* antigens. *Vaccine* **24**:3793–3803.
 151. **Skirrow, M. B., and M. J. Blaser.** 2000. Clinical aspects of *Campylobacter* infection, p. 69–88. In I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 152. **Skirrow, M. B., D. M. Jones, E. Sutcliffe, and J. Benjamin.** 1993. *Campylobacter* bacteraemia in England and Wales, 1981–91. *Epidemiol. Infect.* **110**:567–573.
 153. **Smith, A., M. Reacher, W. Smerdon, G. K. Adak, G. Nichols, and R. M. Chalmers.** 2006. Outbreaks of waterborne infectious intestinal disease in England and Wales, 1992–2003. *Epidemiol. Infect.* **134**:1141–1149.
 154. **Smith, C. K., P. Kaiser, L. Rothwell, T. Humphrey, P. A. Barrow, and M. A. Jones.** 2005. *Campylobacter jejuni*-induced cytokine responses in avian cells. *Infect. Immun.* **73**:2094–2100.
 155. **Sorvillo, F. J., L. E. Lieb, and S. H. Waterman.** 1991. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. *J. Acquir. Immune Defic. Syndr.* **4**:598–602.
 156. **Spiller, R. C.** 2007. Role of infection in irritable bowel syndrome. *J. Gastroenterol.* **42**(Suppl. 17):41–47.
 157. **Strid, M. A., J. Engberg, L. B. Larsen, K. Begtrup, K. Molbak, and K. A. Krogh.** 2001. Antibody responses to *Campylobacter* infections determined by an enzyme-linked immunosorbent assay: 2-year follow-up study of 210 patients. *Clin. Diagn. Lab. Immunol.* **8**:314–319.
 158. **Taylor, D. N., P. Echeverria, C. Pitarangsi, J. Seriwatana, L. Bodhidatta, and M. J. Blaser.** 1988. Influence of strain characteristics and immunity on the epidemiology of *Campylobacter* infections in Thailand. *J. Clin. Microbiol.* **26**:863–868.
 159. **Teunis, P., W. Van den Brandhof, M. Nauta, J. Wagenaar, K. H. Van den, and W. Van Pelt.** 2005. A reconsideration of the *Campylobacter* dose-response relation. *Epidemiol. Infect.* **133**:583–592.
 160. **Teunis, P. F., and A. H. Havelaar.** 2000. The beta Poisson dose-response model is not a single-hit model. *Risk Anal.* **20**:513–520.
 161. **Thompson, J. S., F. E. Cahoon, and D. S. Hodge.** 1986. Rate of *Campylobacter* spp. isolation in three regions of Ontario, Canada, from 1978 to 1985. *J. Clin. Microbiol.* **24**:876–878.
 162. **Thornley, J. P., D. Jenkins, K. Neal, T. Wright, J. Brough, and R. C. Spiller.** 2001. Relationship of *Campylobacter* toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. *J. Infect. Dis.* **184**:606–609.
 163. **Tsukada, S., D. C. Saffran, D. J. Rawlings, O. Parolini, R. C. Allen, I. Klisak, R. S. Sparkes, H. Kubagawa, T. Mohandas, and S. Quan.** 1993. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. *Cell* **72**:279–290.
 164. **van de Putte, L. B., J. H. Berden, M. T. Boerbooms, W. H. Muller, J. J. Rasker, A. Reynvaan-Groendijk, and S. M. van der Linden.** 1980. Reactive arthritis after *Campylobacter jejuni* enteritis. *J. Rheumatol.* **7**:531–535.
 165. **van der Pol, W. L., L. H. Van den Berg, R. H. Scheepers, J. G. van der Bom, P. A. van Doorn, R. van Koningsveld, M. C. van den Broek, J. H. Wokke, and J. G. van der Winkel.** 2000. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. *Neurology* **54**:1661–1665.
 166. **Van Pelt, W., M. A. de Wit, W. J. Wannet, E. J. Ligtoet, M. A. Widdowson, and Y. T. van Duynhoven.** 2003. Laboratory surveillance of bacterial gastroenteric pathogens in The Netherlands, 1991–2001. *Epidemiol. Infect.* **130**:431–441.
 167. **Van Pelt, W., W. J. Wannet, A. W. van de Giessen, D. J. Mevius, and Y. T. van Duynhoven.** 2004. Trends in gastro-enteritis van 1996–2003. *Infect. Bull.* **9**:335–341.
 168. **Van Rhijn, I., L. H. Van den Berg, C. W. Ang, J. Admiraal, and T. Logtenberg.** 2003. Expansion of human gammadelta T cells after in vitro stimulation with *Campylobacter jejuni*. *Int. Immunol.* **15**:373–382.
 169. **van Sorge, N. M., W. L. van der Pol, M. D. Jansen, K. P. Geleijns, S. Kalmijn, R. A. Hughes, J. H. Rees, J. Pritchard, C. A. Vedeler, K. M. Myhr, C. Shaw, I. N. van Schaik, J. H. Wokke, P. A. van Doorn, B. C. Jacobs, J. G. van de Winkel, and L. H. Van den Berg.** 2005. Severity of Guillain-Barre syndrome is associated with Fc gamma receptor III polymorphisms. *J. Neuroimmunol.* **162**:157–164.
 170. **Vedeler, C. A., G. Raknes, K. M. Myhr, and H. Nyland.** 2000. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome. *Neurology* **55**:705–707.
 171. **Vellinga, A., and F. Van Loock.** 2002. The dioxin crisis as experiment to

- determine poultry-related campylobacter enteritis. *Emerg. Infect. Dis.* **8**:19–22.
172. **Vetrie, D., I. Vorechovsky, P. Sideras, J. Holland, A. Davies, F. Flinter, L. Hammarstrom, C. Kinnon, R. Levinsky, and M. Bobrow.** 1993. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. *Nature* **361**:226–233.
 173. **Wassenaar, T. M.** 1997. Toxin production by *Campylobacter* spp. *Clin. Microbiol. Rev.* **10**:466–476.
 174. **Wassenaar, T. M., M. Kist, and A. de Jong.** 2007. Re-analysis of the risks attributed to ciprofloxacin-resistant *Campylobacter jejuni* infections. *Int. J. Antimicrob. Agents* **30**:195–201.
 175. **Watson, R. O., and J. E. Galan.** 2005. Signal transduction in *Campylobacter jejuni*-induced cytokine production. *Cell. Microbiol.* **7**:655–665.
 176. **Watson, R. O., and J. E. Galan.** 2008. *Campylobacter jejuni* survives within epithelial cells by avoiding delivery to lysosomes. *PLoS Pathog.* **4**:e14.
 177. **Watson, R. O., V. Novik, D. Hofreuter, M. Lara-Tejero, and J. E. Galan.** 2007. A MyD88-deficient mouse model reveals a role for Nramp1 in *Campylobacter jejuni* infection. *Infect. Immun.* **75**:1994–2003.
 178. **Weber, P., M. Koch, W. R. Heizmann, M. Scheurle, H. Jentsch, and F. Hartmann.** 1992. Microbic superinfection in relapse of inflammatory bowel disease. *J. Clin. Gastroenterol.* **14**:302–308.
 179. **Wheeler, J. G., D. Sethi, J. M. Cowden, P. G. Wall, L. C. Rodrigues, D. S. Tompkins, M. J. Hudson, P. J. Roderick, et al.** 1999. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. *BMJ* **318**:1046–1050.
 180. **Williams, M. D., J. B. Schorling, L. J. Barrett, S. M. Dudley, I. Orgel, W. C. Koch, D. S. Shields, S. M. Thorson, J. A. Lohr, and R. L. Guerrant.** 1989. Early treatment of *Campylobacter jejuni* enteritis. *Antimicrob. Agents Chemother.* **33**:248–250.
 181. **Willison, H. J.** 2005. The immunobiology of Guillain-Barre syndromes. *J. Peripher. Nerv. Syst.* **10**:94–112.
 182. **Willison, H. J., and G. M. O'Hanlon.** 2000. Anti-glycosphingolipid antibodies and Guillain-Barre syndrome, p. 241–258. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 183. **World Health Organization.** 2001. The increasing incidence of human campylobacteriosis, p. 19–25. World Health Organization, Geneva, Switzerland.
 184. **Young, K. T., L. M. Davis, and V. J. Dirita.** 2007. *Campylobacter jejuni*: molecular biology and pathogenesis. *Nat. Rev. Microbiol.* **5**:665–679.
 185. **Young, V. B., D. B. Schauer, and J. G. Fox.** 2000. Animal models of *Campylobacter* infection, p. 287–302. *In* I. Nachamkin and M. J. Blaser (ed.), *Campylobacter*, 2nd ed. ASM Press, Washington, DC.
 186. **Yrios, J. W., and E. Balish.** 1986. Pathogenesis of *Campylobacter* spp. in athymic and euthymic germfree mice. *Infect. Immun.* **53**:384–392.
 187. **Yuki, N.** 1997. Molecular mimicry between gangliosides and lipopolysaccharides of *Campylobacter jejuni* isolated from patients with Guillain-Barre syndrome and Miller Fisher syndrome. *J. Infect. Dis.* **176**(Suppl. 2):S150–S153.
 188. **Yuki, N., M. Takahashi, Y. Tagawa, K. Kashiwase, K. Tadokoro, and K. Saito.** 1997. Association of *Campylobacter jejuni* serotype with antiganglioside antibody in Guillain-Barre syndrome and Fisher's syndrome. *Ann. Neurol.* **42**:28–33.
 189. **Yuki, N., T. Taki, F. Inagaki, T. Kasama, M. Takahashi, K. Saito, S. Handa, and T. Miyatake.** 1993. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. *J. Exp. Med.* **178**:1771–1775.
 190. **Zilbauer, M., N. Dorrell, A. Elmi, K. J. Lindley, S. Schuller, H. E. Jones, N. J. Klein, G. Nunez, B. W. Wren, and M. Bajaj-Elliott.** 2007. A major role for intestinal epithelial nucleotide oligomerization domain 1 (NOD1) in eliciting host bactericidal immune responses to *Campylobacter jejuni*. *Cell. Microbiol.* **9**:2404–2416.